Skip to main
OMDA

OMDA Stock Forecast & Price Target

OMDA Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Omada Health Inc. reported a remarkable total revenue growth of 49.5% year-over-year, driven by a surge in membership that reached 831,000, significantly surpassing expectations. The company's gross margins expanded to 68.2%, benefiting from an efficient program mix and the integration of AI into its care teams, indicating improved operational efficiencies. Additionally, the forecast suggests continued strong growth with expectations of exceeding 50% revenue growth in FY25, alongside positive EBITDA margin expansion, positioning the company favorably in the evolving cardiometabolic health market.

Bears say

Omada Health Inc. faces a negative outlook primarily due to concerns regarding the sustainability of its growth, particularly as reliance on GLP-1 medications may lead to a slowdown in revenue growth to approximately 20%. Additionally, while the company is investing in a new GLP-1 care track, the anticipated ramp in adjusted EBITDA is expected to decelerate post-2025, complicating its long-term profitability trajectory. Furthermore, increasing competition in the GLP-1 space is placing downward pressure on prices, which may negate cost reductions expected by employers and payors, emphasizing the necessity for enhanced management solutions to optimize delivery.

OMDA has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omada Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omada Health Inc (OMDA) Forecast

Analysts have given OMDA a Buy based on their latest research and market trends.

According to 10 analysts, OMDA has a Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omada Health Inc (OMDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.